

# Benjamin Mizukawa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3981649/publications.pdf>

Version: 2024-02-01

31  
papers

671  
citations

1040056

9  
h-index

752698

20  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1736  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia. <i>Leukemia</i> , 2022, 36, 637-647.	7.2	5
2	Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis. <i>Nature Communications</i> , 2022, 13, .	12.8	3
3	PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 642466.	2.8	14
4	V2 Trial: A phase I study of venetoclax and CPX-351 for young patients with relapsed/refractory acute leukemia.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS7052-TPS7052.	1.6	1
5	Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Shortâ€course EPOCH regimens are safe and effective. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29126.	1.5	5
6	Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. <i>Journal of Clinical Oncology</i> , 2021, 39, 3822-3828.	1.6	4
7	Hyperdiploid Precursor B-acute Lymphoblastic Leukemia Presenting as a Cavernous Sinus Mass in a 4-Year-old Male. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e494-e497.	0.6	0
8	FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML. <i>Nature Communications</i> , 2020, 11, 928.	12.8	54
9	Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro. <i>Experimental Hematology</i> , 2020, 86, 21-27.e2.	0.4	11
10	Methylation profiling of hypomethylating agent response and treatment failure in pediatric and young adult MDS/AML.. <i>Journal of Clinical Oncology</i> , 2020, 38, e22502-e22502.	1.6	0
11	Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia. <i>Nature Communications</i> , 2019, 10, 4869.	12.8	36
12	Improved chemotherapy modeling with RAG-based immune deficient mice. <i>PLoS ONE</i> , 2019, 14, e0225532.	2.5	21
13	V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia. <i>Blood</i> , 2019, 134, 3830-3830.	1.4	1
14	The Small Molecule IODVA1 Inhibits the Rac Guanine Nucleotide Exchange Factor Vav3 and Overcomes TKI-Resistance in Ph+(BCR-ABL1) B-ALL. <i>Blood</i> , 2019, 134, 4647-4647.	1.4	0
15	Cell Polarity and Division Symmetry Analyses in Transformed Blood Cells. <i>Methods in Molecular Biology</i> , 2018, 1821, 257-266.	0.9	0
16	A novel in vitro approach for the identification of exceptional responders in acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2018, 36, e19011-e19011.	1.6	0
17	Proton Sensor GPR68 Is Essential to Maintain Myeloid Malignancies. <i>Blood</i> , 2018, 132, 1353-1353.	1.4	0
18	A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (VyxeosÂ®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia. <i>Blood</i> , 2018, 132, 336-336.	1.4	0

#	ARTICLE	IF	CITATIONS
19	In Vitro Approach for the Identification of Exceptional Responders in Acute Myeloid Leukemia. Blood, 2018, 132, 2212-2212.	1.4	0
20	Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted <sc>EPOCH</sc>. British Journal of Haematology, 2017, 179, 739-747.	2.5	101
21	Molecular signatures and responses to targeted therapies in over 300 relapsed and therapy-refractory young adult (AYA) and childhood cancers.. Journal of Clinical Oncology, 2017, 35, 11514-11514.	1.6	0
22	Protease-Activated Receptor 1 (PAR-1) Inhibits Proliferation but Enhances Leukemia Stem Cell Activity in Acute Myeloid Leukemia. Blood, 2016, 128, 2730-2730.	1.4	2
23	A phase I/pilot study of CPX-351 for children, adolescents and young adults with recurrent or refractory hematologic malignancies.. Journal of Clinical Oncology, 2016, 34, 10541-10541.	1.6	6
24	A Xenograft Model of Lymphocyte-Independent, Effector-Driven Macrophage Activation Syndrome Amenable to Anti-CD33 and Anti-IL-6R Treatment. Blood, 2016, 128, 3684-3684.	1.4	0
25	Functional Niche Competition Between Normal Hematopoietic Stem and Progenitor Cells and Myeloid Leukemia Cells. Stem Cells, 2015, 33, 3635-3642.	3.2	40
26	Cooperating G6PD mutations associated with severe neonatal hyperbilirubinemia and cholestasis. Pediatric Blood and Cancer, 2011, 56, 840-842.	1.5	8
27	AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia, 2010, 24, 1785-1788.	7.2	341
28	Adaptation of a Xenograft AML Model to Evaluate Chemotherapeutic Efficacy In Vivo. Blood, 2010, 116, 3304-3304.	1.4	1
29	A Novel Method of Mobilizing Leukemia Initiating Cells by a Small Molecule Cdc42 Activity-Specific Inhibitor (CASIN) for Acute Myeloid Leukemia Therapy.. Blood, 2009, 114, 13-13.	1.4	4
30	A New Immunodeficient Mouse Strain, NOD/SCID IL2R <sup>3</sup> /S <sup>3</sup> SGM3, Promotes Enhanced Human Hematopoietic Cell Xenografts with a Robust T Cell Component.. Blood, 2009, 114, 3524-3524.	1.4	13
31	Bcl-XL Is a Critical Mediator of Rac Signaling in MLL-AF9-Induced Acute Myeloid Leukemia.. Blood, 2009, 114, 1971-1971.	1.4	0